JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, L L
Right arrow Articles by Jungkind, D L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, L L
Right arrow Articles by Jungkind, D L
J Clin Microbiol. 1983 August; 18(2): 389-394

False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime.

L L Stone and D L Jungkind

ABSTRACT

The MS-2 system (Abbott Laboratories) was used for cefotaxime and moxalactam susceptibility testing of 111 Pseudomonas aeruginosa isolates collected from our burn treatment center. The frequency of very major errors was 52% for moxalactam and 32% for cefotaxime for all isolates requiring a minimal inhibitory concentration of greater than or equal to 64 micrograms/ml. For isolates requiring a minimal inhibitory concentration of 64 micrograms/ml, the very major errors were 78% for moxalactam and 57% for cefotaxime. Testing of an additional 44 isolates collected from another hospital confirmed that these results were not unique to nosocomial strains from within the burn center. The ratio of errors did not change when MS-2 results were compared with disk diffusion results. Colony count testing done on cuvettes which produced false-susceptible results indicated that little numerical change occurred during the 5- to 6-h test cycle, whereas microscopy of cuvette contents revealed metabolically active filamentous bacilli. The high frequency of false-susceptible results indicated that the MS-2 should not be used for testing clinical P. aeruginosa isolates for resistance to the two third-generation cephalosporins currently available for the MS-2. A comparison of the disk diffusion results indicated that neither moxalactam nor cefotaxime could be reliably used for predictive, class-concept testing of P. aeruginosa.


J Clin Microbiol. 1983 August; 18(2): 389-394







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1983 by the American Society for Microbiology. All rights reserved.